Is There an Association between Migraine and Gastrointestinal Disorders?

Michael Doulberis, Christian Saleh, Stefan Beyenburg

Migraine is a primary episodic headache disorder that represents a substantial burden and disability worldwide. Its pathogenesis is multifactorial and remains hitherto poorly elucidated. An interesting but less-well-known association is that between migraine and gastrointestinal disorders. We have reviewed the literature for relevant papers reporting on the clinical association between migraine and gastrointestinal symptoms. Several studies have shown different gastrointestinal diseases to be associated with migraine, but the underlining pathophysiology remains elusive. The data gathered and analyzed have shown great variability across studies, making it impossible to draw definitive conclusions. Further research is required to elucidate this potential relationship. An understanding of the relationship between migraine and gastrointestinal disorders is of great clinical importance for prompt diagnosis and treatment.

Key Words: headache, migraine, gut-brain axis, inflammatory bowel disease, gastrointestinal diseases, irritable bowel syndrome, Helicobacter pylori infection.

INTRODUCTION

Migraine is a recurrent primary headache disorder with a prevalence of 8.6% in males and 17.5% in females. Migraines are among the most disabling and burdensome conditions. The Global Burden of Disease Study ranked migraine as the seventh most common disabling pathalogy among 289 diseases, being referred to as the 7th disabler. Migraine has a significant impact on both mental and physical health, since it can impair school or work performance so as to substantially decrease the quality of life, leading to social isolation. The problem becomes even more significant when various comorbidities such as autoimmune, gastrointestinal (GI), and psychiatric diseases are taken into account. Nevertheless, the pathophysiological mechanism of migraine remains elusive. Several mechanisms such as inflammation, pain mediators such as calcitonin-gene-related peptide (CGRP), and neurotransmitters such as serotonin are currently discussed; indeed, serotonin agonists such as triptans can relieve migraine, and selective serotonin-reuptake inhibitors and tricyclic antidepressants have been used successfully as prophylactic treatments.

There is emerging research evidence for the GI system playing an important role in the pathophysiology of migraine. A possible connection was initially prompted by the observation that GI symptoms such as nausea, vomiting, and gastroparesis constitute clinical hallmarks of migraine. Moreover, abdominal migraine, a condition that presents with both migrainous and abdominal symptoms, suggests that a common mechanism underlies both affected systems. Furthermore, migraines can often coexist with GI disorders (GID) such as inflammatory bowel disease (IBD), celiac disease (CD), irritable bowel syndrome (IBS), and Helicobacter pylori (H. pylori) infection (HPI). Moreover, GI tract (GIT) mi-
crobiota have been implicated in the pathogenesis of more than 25 diseases with CNS effects, for which multiple mechanisms have been discussed, such as bacterial translocation secondary to an impaired intestinal barrier, migration of stimulated immune cells, and the systemic diffusion of microbial products or metabolites.8,20 This complex interplay between the brain and GIT is referred to in the literature as the gut-brain axis, which involves immune, neuroendocrine, and metabolic pathways, although the precise pathophysiology linking the different GI entities with migraine remains unclear.8,10

This paper is aimed at clinicians due to there being little

| Authors (year)          | Country     | Sample size | n (females/males) | Mean age, years |
|-------------------------|-------------|-------------|-------------------|-----------------|
| Aamodt et al. (2008)    | Norway      | 43,782      | 12,944/6,898      | 46.2            |
| Alehan et al. (2008)    | Turkey      | 220         | 41/32             | 12.01           |
| Alpay et al. (2010)     | Turkey      | 30          | 28/2              | 35              |
| Amery and Forget (1989) | Belgium     | 16          | NM                | NM              |
| Aurora et al. (2006)    | USA         | 10          | NM                | 24.1            |
| Aydinalar et al. (2013) | Turkey      | 21          | 18/3              | 38              |
| Bektas et al. (2017)    | Turkey      | 49/49       | 41/8 (controls: NM) | 38.38 (controls: 36.93) |
| Ben-Or et al. (2015)    | Israel      | 50          | 24/26             | 14.8            |
| Boccia et al. (2006)    | Italy       | 50          | 29/21             | 8.6             |
| Bradbeer et al. (2013)  | Australia   | 1           | 1/0               | 7               |
| Bürk et al. (2009)      | Germany     | 72          | 62/10             | 51              |
| Cheraghi et al. (2016)  | Iran        | 80          | 33/47 (controls: 36/44) | 35.31 (controls: 34.69) |
| Christensen et al. (2008) | USA     | 67          | 52/15             | 43.7            |
| Cole et al. (2006)      | USA         | 97,593      | 70,475/27,118     | NM              |
| Cupini et al. (2003)    | Italy       | 1           | 1/0               | 19              |
| Dimitrova et al. (2013) | USA         | 502         | Controls (178: 109/69) | Controls: 47.8 |
| Egger et al. (1983)     | UK          | 88          | 48/40             | 9.83            |
| Gabrielli et al. (2003) | Italy       | 90          | 63/27             | 37              |
| Gunay et al. (2013)     | USA         | 81          | 65/16             | 40              |
| Hirst and Noble (2009)  | UK          | 3           | 2/1               | Males: 55, females: 20.48 |
| Hosseinzadeh et al. (2011) | Iran   | 70          | 46/24             | 35              |
| Kurth et al. (2006)     | Germany     | 99          | 75/24             | 41.5            |
| Maniyan et al. (2014)   | USA         | 27          | 24/3              | 32              |
| Mitchell et al. (2011)  | UK          | 167 (sham diet: 83, true diet: 84) | Sham diet: 72/11 true diet: 75/9 | 47.7 (sham diet: 47.1, true diet: 48.3) |
| Monro et al. (1984)     | UK          | 9           | 6/3               | 45.7            |
| Park et al. (2013)      | Korea       | 109         | 95/14             | 41              |
| Robbins (2014)          | USA         | 1           | 0/1               | 20              |
| Romanello et al. (2013) | Italy       | 208         | 86/122            | NM              |
| Ruggieri et al. (2008)  | Italy       | 835         | 604/231           | 7.8             |
| Sillanpää and Saarinen (2015) | Finland     | 787         | 434/356           | 18              |
| Soares et al. (2013)    | Brazil      | 330         | 177/173           | Group I: 27.6   |
| Watson et al. (1978)    | UK          | 90          | 90/0              | NM              |
| Yiannopoulou et al. (2007) | Greece  | 49          | 37/12             | Group II: 34.6  |
| Zaki et al. (2009)      | USA         | CVS: 30, adult MoA: 112 | CVS: 21/9; MoA: NM | NM |

CD: celiac disease, CVS: cyclic vomiting syndrome, GS: gluten sensitivity, IBD: inflammatory bowel disease, MoA: migraine without aura, NM: not mentioned.
Table 2. Study design

| Authors (year)          | Main GI disease             | Comorbidities | Migraine duration, years | Inclusion criteria                                                                 | Exclusion criteria                                      | Maximum follow-up, months |
|-------------------------|------------------------------|---------------|--------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------|----------------------------|
| Aamodt et al. (2008)    | Reflux                       | NM            | 1                        | 1. Age >20 years 2. ≥1 headache in previous year                                    | NM                                                      | NM                        |
| Alehan et al. (2008)    | CD                           | NM            | 1                        | 1. Age 6–17 years 2. IHS criteria                                                  | See inclusion criteria                                  | NM                        |
| Alpay et al. (2010)     | Food allergy                 | NM            | 13±9 (mean±SD)           | 1. ≥4 attacks or headaches/month 2. Age 18–55 years 3. Treatment only with acute/preventive medication unchanged for ≥3 months 4. Cooperation | 1. Medication overuse 2. Pure menstrual migraine         | 6 weeks                   |
| Amery and Forget (1989) | Recurrent abdominal pain disorder | NM      | NM                       | Recurrent abdominal pain                                                           | NM                                                      | NM                        |
| Aurora et al. (2006)    | Gastric stasis               | NM            | NM                       | 1. Migraneurs (IHS) 2. Sensitivity to visual triggers                              | 1 Daily usage of centrally acting medications 2. Egg allergy 3. Prokinetic substances 4. Frequent tension-type headaches, chronic headache, and/or chronic opioid use | NM                        |
| Aydinlar et al. (2013)  | IBS                          | NM            | 10.8                     | 1. Migraine duration ≥6 months and at least 2 migraine attacks and 4 headache days during the previous month 2. Age 18–65 years 3. Abdominal discomfort lasting ≥12 weeks during previous year 4. Preventive medications unchanged for ≥6 months | 1. Medication-overuse headache, pure menstrual migraine 2. IBD, CD, lactose intolerance 3. Major abdominal surgery | 4.5                       |
| Bektas et al. (2017)    | Food allergy                 | NM            | 5.5                      | 1. Migraine without aura and healthy controls                                      | 1. History of allergy or systemic illness 2. Intake of H2-receptor blockers or antiallergic medication 3. Antidepressants discontinued <1 week prior to study beginning | NM                        |
| Ben-Or et al. (2019)    | IBD                          | NM            | 0.75 (mean)              | 1. Clinically and histologically proven IBD 2. Questionnaire                       | NM                                                      | NM                        |
| Authors (year)               | Main GI disease          | Comorbidities | Migraine duration, years | Inclusion criteria                                                                 | Exclusion criteria                                                                 | Maximum follow-up, months |
|-----------------------------|--------------------------|---------------|--------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|---------------------------|
| Boccia et al. (2006)<sup>40</sup> | Diffuse GI symptoms     | NM            | NM                       | 1. Questionnaire                                                                   | 1. Head trauma                                                                     | 2                         |
|                             |                          |               |                          | 2. Rome II criteria for functional dyspepsia, IBS, functional abdominal pain, abdominal migraine, CVS | 2. Vascular complications                                                           |                           |
|                             |                          |               |                          | 3. Functional vomiting (adult FGID criteria)                                        | 3. Head or neck surgery                                                             |                           |
|                             |                          |               |                          |                                                                                   | 4. Brain tumor                                                                     |                           |
|                             |                          |               |                          |                                                                                   | 5. Lumbar puncture                                                                 |                           |
| Bradbeer et al. (2013)<sup>41</sup> | H. pylori infection     | None          | 8 months                 | 1. Depression                                                                      | 1. Past medical history of a disorder commonly contributed to headache               |                           |
|                             |                          |               |                          | 2. Personality changes                                                             | 2. Lumbar puncture within the past 3 years                                            |                           |
|                             |                          |               |                          | 3. Psychosis                                                                       | 3. Past surgeries of the head and neck                                              |                           |
|                             |                          |               |                          | 4. Hashimoto's disease                                                             | 4. Dual diagnoses                                                                   |                           |
| Bürk et al. (2009)<sup>27</sup> | CD                      | 8             | Biopsy-proven diagnosis   |                                                                                   |                                                                                     |                           |
| Cheraghi et al. (2016)<sup>10</sup> | IBD                     | NM            | NM                       | 1. Age >18 years                                                                   |                                                                                     |                           |
|                             |                          |               |                          | 2. IBD                                                                             |                                                                                     |                           |
|                             |                          |               |                          | 3. Informed consent                                                                |                                                                                     |                           |
| Christensen et al. (2008)<sup>13</sup> | DGP                    | NM            | NM                       | Other identifiable causes of nausea and vomiting                                    |                                                                                     |                           |
| Cole et al. (2008)<sup>14</sup> | IBS                     | NM            | NM                       |                                                                                   |                                                                                     |                           |
| Cupini et al. (2003)<sup>11</sup> | CVS                     | 1. Epilepsy    | Since infancy             |                                                                                   |                                                                                     |                           |
| Dimitrova et al. (2013)<sup>25</sup> | CD with IBD             | NM            | NM                       |                                                                                   |                                                                                     |                           |
| Egger et al. (1983)<sup>10</sup> | Food allergy            | NM            | 0.5–11                   | ≥1 headache/week during the previous year with ≥2 of the following: pallor, nausea, abdominal pain, photophobia, visual disturbances, giddiness/weakness, paresthesia | Heads due to middle-ear disease, sinusitis, refractive errors, dental disease, raised blood pressure, or intracranial hypertension | 0                         |
| Gabrielli et al. (2003)<sup>32</sup> | CD                      | NM            | NM                       |                                                                                   |                                                                                     | 6                         |
| Authors (year) | Main GI disease | Comorbidities | Migraine duration, years | Inclusion criteria | Exclusion criteria | Maximum follow-up, months |
|---------------|-----------------|---------------|--------------------------|-------------------|-------------------|--------------------------|
| Gunay et al. (2013) | Roux-en-Y gastric bypass | 1. Sleep apnea, menstrual dysfunction, depression, anxiety 2. Hypertension, hyperlipidemia, type 2 diabetes mellitus | 22.6 | 1. Preoperative migraine with antimigraine medication use 2. Postoperative follow-up of >12 months | 1. See inclusion criteria 2. Physician-diagnosed idiopathic intracranial hypertension carefully identified to exclude them from the Migraine-Headache study | 38.6 |
| Hirst and Noble (2009) | Cancer | Esophageal cancer, ovarian germ-cell tumor, severe intractable nausea | 3 months (pt 1), 4 years (pt 2), NM (pt 3) | NM | NM | NM |
| Hosseinzeideh et al. (2011) | H. pylori infection | Reflux, gastric ulcer, gastritis | NM | NM | NM | NM |
| Kurth et al. (2006) | Upper abdominal symptoms | NM | NM | NM | NM | NM |
| Maniyar et al. (2014) | Nausea | NM | NM | Migraine aura | NM |
| Mitchell et al. (2011) | Food allergy | NM | ≥1 | 1. Age 18–65 years 2. Migraine without aura 3. <15 days of headache/month 4. Premonitory symptoms before headache 5. No major medical conditions, and not taking preventive drugs for migraine or any other regular medications | See inclusion criteria | 3 |
| Monro et al. (1984) | Food allergy | NM | NM | NM | NM |
| Park et al. (2013) | Functional GI symptoms | 1. Headache-related disability 2. Psychological comorbidities | 9.8 | NM | 1. Severe systemic disease 2. History of abdominal surgery 3. GI disorder 4. Analgesics for headache >10 times during previous 3 months | NM |
| Robbins (2014) | IBS | Episodic tension-type headache (no attacks during periods of abdominal pain) | 14 | NM | NM | NM |
| Authors (year) | Main GI disease | Comorbidities | Migraine duration, years | Inclusion criteria | Exclusion criteria | Maximum follow-up, months |
|----------------|-----------------|---------------|--------------------------|-------------------|------------------|--------------------------|
| Romanello et al. (2013) | Infantile colic | 1. Asthma 2. Diabetes 3. rUTI 4. SCD | NM | 1. Migraine and tension-type headache 2. Age 6–18 years | Primary headaches | NM |
| Ruggieri et al. (2008) | GS | 1. Neurofibromatosis type 1 & 2 2. Tubrous sclerosis complex 3. Complex malformation syndromes 4. Cerebellar degeneration 5. Multiple sclerosis 6. Known leukodystrophies 7. Ataxia-telangiectasia 8. Congenital myasthenia syndromes 9. Congenital muscular dystrophies | NM | 1. Pediatric population from southern Italy 2. GS with or without enteropathy | NM | 8.7 |
| Sillanpää and Saarinen (2015) | Infantile colic | 1. Allergic diseases 2. Backache 3. Sleep disturbances | NM | Questionnaire/visits | NM | 210 |
| Soares et al. (2013) | IBS | NM | NM | 1. Rome III criteria for IBS 2. ICHD-II criteria for primary headache | Diagnostic suspicion of organic disease of GIT | NM |
| Watson et al. (1978) | IBS | IBS | NM | IBS | 1. Abuse of laxatives 2. Pathological sigmoidoscopy | NM |
| Yiannopoulou et al. (2007) | H. pylori infection | H. pylori infection | 1–20 | Migraine without aura | NM | NM |
| Zaki et al. (2009) | CVS | (Neuromuscular disease) | Positive for mtDNA haplogroup H | See inclusion criteria | NM |

CD: celiac disease, CVS: cyclic vomitings syndrome, DGP: diabetic gastropathy, ELISA: enzyme linked immunosorbent assay, FGID: functional gastrointestinal disorders, GI: gastrointestinal, GIT: gastrointestinal tract, GS: gluten sensitivity, H. pylori: Helicobacter pylori, IBD: inflammatory bowel disease, IBS: irritable bowel syndrome, ICHD: International Classification of Headache Disorders, IHS: International Headache Society, NM: not mentioned, pt: patient, rUTI: recurrent urinary tract infection, SCD: Sickle-cell disease.
### Table 3. GI manifestations and possible pathogenetic mechanisms underlying the correlation between the CNS and GID

| Authors (year)               | GI symptoms                                                                 | Likely mechanism underlying GID/CNS correlation                                                                 |
|------------------------------|------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Aamodt et al. (2008)¹⁰       | 1. Reflux 2. Constipation 3. Nausea                                          | Autonomic nervous system dysfunction                                                                           |
| Alehan et al. (2008)²⁸       | Study focus: asymptomatic CD                                                   | Autoimmune mediated                                                                                           |
| Alpay et al. (2010)²⁵        | NM                                                                           | Inflammation induced by allergen-specific IgG or mediated by histamine                                         |
| Amery and Forget (1989)⁴⁵    | Periumbilical pain                                                            | Increased gut permeability, leading to cerebral vasoconstriction                                              |
| Aurora et al. (2006)⁴⁰       | Nausea                                                                       | Autonomic nervous system dysfunction (in migraineurs) and gastric stasis                                      |
| Aydınlar et al. (2013)²²     | Pain, bloating, diarrhea, and constipation                                     | Immunological and inflammatory process                                                                        |
| Bektaş et al. (2017)³⁵       | 1. Nausea 2. Vomiting                                                        | Allergens may lead to activation of trigeminal afferents through an enhancement of the release of inflammatory mediators |
| Ben-Or et al. (2015)²³       | 1. Abdominal pain 2. Diarrhea 3. Weight loss 4. Anal fistulas                 | Autoimmune process or cross-reactivity; inflammatory process, malabsorption with hypovitaminosis            |
| Boccia et al. (2006)⁴⁰       | 1. Functional vomiting 2. Functional abdominal pain                          | Channelopathy                                                                                                 |
| Bradbeer et al. (2013)²³     | Intermittent diffuse abdominal discomfort with nausea (independent of headaches) | Infected gastric mucosa that activates proinflammatory factors, which induce systemic vasospasm                |
| Bürk et al. (2009)²⁷         | NM                                                                           | Immune hypothesis                                                                                             |
| Cheraghi et al. (2016)²⁰     | NM                                                                           | Anxiety as well as inflammation via CRP, MMP-9, cytokines, and adhesion molecules                            |
| Christensen et al. (2008)²³  | Bloating, early satiety, abdominal pain, nausea, vomiting (all parameters separately graduated) | Mitochondrial, metabolic, endocrine factors, vagal cholinergic dysfunction                                    |
| Cole et al. (2006)¹⁶         | NM                                                                           | Common pathological pathway                                                                                   |
| Cupini et al. (2003)³¹       | Nonspecific GI symptoms                                                      | Mitochondrial DNA mutations, ion channelopathies, excessive endocrine dysfunction, heightened autonomic reactivity, genetic factors |
| Dimitrova et al. (2013)³⁵    | NM                                                                           | 1. Inflammatory process (CRP, MMP-9, cytokines, adhesion molecules, NF-κB, iNOS) 2. Immunological process |
| Egger et al. (1983)³⁶         | 1. Abdominal pain, diarrhea, flatulence 2. Recurrent mouth ulcers            | 1. Allergic reaction topical in the gut and release of mediators or in systemic circulation of antibody-antigen-complex 2. Platelet dysfunction |
| Gabrielli et al. (2003)³⁶    | Recurrent abdominal pain, chronic diarrhea, bloating                         | Autoimmune process                                                                                           |
| Gunay et al. (2013)²⁹        | NM                                                                           | 1. Inflammatory mediators and endocrine hormones (neuropeptides) 2. Psychological factors: stress, anxiety, depression 3. Behavioral factors: sleep disturbances, sleep apnea, dietary irregularities, low physical activity |
| Hirst and Noble (2009)²⁵     | Nausea, vomiting                                                             | Impaired autonomic function                                                                                   |
| Hosseinzadeh et al. (2011)²⁹| Nonspecific GI symptoms                                                      | Serotonin mediated (secondary to H. pylori induction)                                                          |
| Kurth et al. (2006)³³        | Abdominal pain, dyspepsia                                                    | Abnormal visceral mechanosensory, vagal function, CGRP                                                        |
| Maniyar et al. (2014)⁴²      | Nausea                                                                       | Nausea, which leads to activation of NTS, dorsal motor nucleus of the vagus, nucleus ambiguus, or PAG, Nausea as a primary event of migraine |
awareness in the broader medical community regarding this relationship. We believe that a better understanding of this association is likely to lead to a GID being considered a potential cause of migraine headache, in turn leading to prompt diagnoses and in fundamental migraine treatments changing from being pure symptomatic to curative.

METHODS

A PubMed search was conducted that included all papers reporting on headache associated with GI symptoms. No time restraint was set. The search was based only on papers written in English, and the keywords used were “headache,” “gastrointestinal diseases,” “migraine,” and “hemicrania.” Using these keywords in various combinations yielded the following results: “headache” AND “gastrointestinal diseases” identified 308 papers, “headache” AND “gastrointestinal disorders” identified 84 articles, “migraine” AND “gastrointestinal diseases” identified 126 articles, and “hemicrania” AND “gastrointestinal diseases” identified 1 article. Further articles were identified through a manual search of the initially revealed literature. Only original studies and case reports/series on possible mechanisms between migraine and GI symptomatology were included.

In total, 29 papers were included for the purposes of this review. Since a common pathophysiological mechanism for migraine associated with GID could not be identified, since the literature searched yielded too many findings of GID concomitant with migraine headache that each had its own pathophysiology, in the Discussion section we present in more detail the reviewed studies and report for each study the potential pathophysiological mechanisms offered by the authors. Since migraine is associated with multiple GI entities rather than a single GID, we have regrouped migraine studies in the Results section according to the associated GID in order to facilitate the overview. Further details on each reviewed study regarding demographics, study characteristics, and pathogenicity-associated parameters are tabulated in Table 1, 2, and 3.

RESULTS

While the pathophysiological mechanism(s) underlying migraine and GID remain(s) elusive, the clinical observations--although being largely anecdotal--suggest that there is an important relationship between these two conditions.

Table 3. GI manifestations and possible pathogenetic mechanisms underlying the correlation between the CNS and GID (continued)

| Authors (year) | GI symptoms | Likely mechanism underlying GID/CNS correlation |
|---------------|-------------|-----------------------------------------------|
| Mitchell et al. (2011) | 1. Nausea 2. Diarrhea | NM |
| Monro et al. (1984) | NM | Immunologically mediated via immune complexes containing IGE |
| Park et al. (2013) | 1. IBS 2. Nausea and vomiting disorders 3. Functional esophageal disorders 4. Functional dyspepsia 5. Functional bloating | Mitochondrial dysfunction, which causes nervous system dysfunction |
| Robbins (2014) | IBS symptoms | Neuroendocrine abnormalities of the hypothalamus |
| Romanello et al. (2013) | Abdominal pain | CGRP mediation |
| Ruggieri et al. (2008) | GS symptomatology | Hypothesis: GS-associated antibodies inducing neurotoxicity |
| Sillanpää and Saarinen (2015) | Infantile colic | NM |
| Soares et al. (2013) | NM | Role of brain–gut axis, neuroimmune and neuroendocrine interactions |
| Watson et al. (1978) | IBS symptoms | Hormonal mechanism |
| Yiannopoulou et al. (2007) | NM | Chronic immunoinflammatory response, which induces systemic vasculopathy |
| Zaki et al. (2009) | 1. Nausea 2. Vomiting 3. Abdominal pain | Mitochondrial dysfunction |

CD: celiac disease, CGRP: calcitonin-gene-related peptide, CNS: central nervous system, CRP: C-reactive protein, GI: gastrointestinal, GID: gastrointestinal disorders, GS: gluten sensitivity, H. pylori: Helicobacter pylori, IBS: irritable bowel syndrome, IGE: Immunoglobulin E, iNOS: inducible nitric oxide synthase, MMP-9: matrix metalloproteinase-9, NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells, NM: not mentioned, NTS: nucleus tractus solitarius, PAG: periaqueductal gray.
Irritable bowel syndrome

Robbins\textsuperscript{21} reported the case of a 20-year-old male experiencing periodic episodes of abdominal pain resembling cluster headache (CH), which lasted 30–120 minutes and manifested in the evenings at intervals of 2–8 weeks. He had also experienced infrequent episodic tension-type headache that did not occur during periods of abdominal pain. A diagnosis of IBS was made, and the eventual relationship between CH and IBS was supported by the observation of the effectiveness of CH prophylaxis (e.g., verapamil) in the treatment of IBS.\textsuperscript{21} Food elimination for the therapeutic management of patients with migraine and IBS was evaluated by Aydinlar et al.\textsuperscript{22} in a double-blind, randomized, controlled, cross-over clinical trial involving 21 patients. Food allergy seems to play an important role in migraine pathophysiology due to a hypothesized inflammatory response.\textsuperscript{23} Those authors reported that the tailored elimination diet resulted in significant improvements in both migraine and IBS symptoms, possibly by reducing the inflammatory response. Watson et al.\textsuperscript{24} postulated a hormonal cause relating headache and IBS, since 50% of their patients had had headache. A neuroendocrine mechanism as a common pathophysiological mechanism underlying IBS and migraine was also postulated by Soares et al.\textsuperscript{25} Cole et al.\textsuperscript{26} found that the likelihood of migraine was 40–80% higher in subjects with IBS than in those without IBS.

Celiac disease

Dimitrova et al.\textsuperscript{27} showed in 502 patients that the prevalence of migraine was higher in patients with CD and IBD than in healthy controls. Some patients reported significant migraine improvement or resolution after consuming a gluten-free diet, and similar findings were also reported by Gabrielli et al.\textsuperscript{28} Bürk et al.\textsuperscript{29} reported on 20 patients with biopsy-proven CD and migraine, finding that a gluten-free diet reduced migraine symptoms in many cases. Alehan et al.\textsuperscript{30} measured serum tissue transglutaminase IgA (tTGA) antibodies (an indicator for the presence of CD) in their cases (73 children with migraine) and controls ($n=147$). The prevalence of tTGA antibodies was higher in migraine patients, suggesting a relationship between migraine and CD. The pathophysiology underlying these two conditions remains unclear, but the authors suggested that multiple nutritional, immunological, and inflammatory factors could be involved in triggering migraine attacks.\textsuperscript{28}

Inflammatory bowel disease

In a case–control study, Ben-Or et al.\textsuperscript{31} examined the prevalence of neurological diseases with GID in 50 patients and 42 healthy subjects, and found that the prevalence of headache was higher in IBD patients than in the control subjects (46% vs. 7.1%). The authors hypothesized an autoimmune/inflammatory mechanism or even malabsorption as possible pathophysiological components. In a cross-sectional study involving 160 subjects (80 with IBD and 80 controls without IBD, with a mean age of 35 years), Cheraghi et al.\textsuperscript{32} found that the prevalence of migraine was significantly higher in subjects with IBD (21.3% vs. 8.8%, $p=0.027$). A potential inflammatory pathophysiological mechanism underlying these two conditions was postulated by the authors.

Cyclic vomiting syndrome

Cupini et al.\textsuperscript{33} observed in a 19-year-old woman with cyclic vomiting syndrome (CVS) and migraine that calcium-channel antagonists such as flunarizine led to a significant improvement of the vomiting syndrome, which led the authors to postulate a common pathogenic mechanism underlying both conditions. A genetic, mitochondrial dysfunction in migraine pathogenesis was postulated by Zaki et al.\textsuperscript{34} Those authors found mitochondrial polymorphisms to be strongly associated in migraine and CVS patients; CVS is considered a migraine-like condition presenting with similar prodromal symptoms of nausea and vomiting that is responsive to anti-migraine medications. Likewise, Christensen et al.\textsuperscript{35} found that the incidence of migraine headaches was higher in patients with CVS and diabetic gastropathy.

Food allergy

Monro et al.\textsuperscript{36} described nine patients with food-provoking migraine who were refractory to conventional migraine therapy, and found that dietary exclusion of the offending food resulted in improvement of the migraine. Alpay et al.\textsuperscript{37} showed in a double-blind, randomized, controlled, cross-over trial involving 30 patients (28 females and 2 males with a mean age of 35 years) that diet restriction in migraineurs based on IgG antibodies reduced the frequency of their migraine attacks (from 9.0 ± 4.4 to 6.2 ± 3.8, $p<0.001$, mean ± SD; $p<0.001$). The authors speculated that inflammatory mechanisms could play a role in migraine. In a randomized controlled trial, Mitchell et al.\textsuperscript{38} investigated the use of food elimination based on the presence of IgG antibodies for the prevention of migraine. The 167 participants had migraine and intolerance to at least one foodstuff, and they were randomized to a sham diet ($n=83$) or the intervention diet ($n=84$). The authors noted a significant decrease in the number of migraines at 4 weeks, but only a small decrease (not statistically significant) over the 12-week study period.

The relation between migraine and allergens was also investigated by Bektas et al.\textsuperscript{39} who enrolled 98 subjects (49 with migraine and 49 healthy subjects, with mean ages of 38.3 and 36.9 years, respectively). The rate of positivity in the...
allergy test was 55.1% in the migraine group and 32.7% in the control group (p<0.05). Allergy positivity was associated with the frequency but not the severity of attacks. An inflammatory mechanism triggered by allergens leading to the vasodilator phase of migraine and local meningeal inflammation was postulated by the authors.

In 1983, Egger et al. reported that 98% of 88 children with severe frequent migraine recovered on an appropriate diet. The authors concluded that since a wide range of foods can provoke an attack, an allergic rather than a metabolic mechanism might be the underlying cause. However, the authors noted that the patients did not show greatly increased levels of IgE or IgE antibodies.

**Helicobacter pylori infection**

A link between HPI and headache was suggested by Bradbeer et al. after they observed that HPI eradication treatment improved the headache but not diffuse abdominal symptoms in a young girl. A particularly interesting finding was that the patient's mother—who was suffering equally from recurrent migraine and GI discomfort—exhibited *H. pylori* positivity; eradication therapy also led to the resolution of her symptoms.

In a case–control study, Hosseinzadeh et al. found that the IgG and IgM antibody titers against *H. pylori* differed significantly between 70 patients with migraine headache and control groups: the optical densities for IgG and IgM antibodies to *H. pylori* were 60.08±7.70 and 32.1±8.7 in the case group and 21.82±6.20 and 17.6±9.4 in the control group. A serotonin-based pathophysiological mechanism underlying both *H. pylori* infection and migraine was hypothesized by the authors, and they emphasized the need to investigate *H. pylori* infection actively in migraine patients.

Equally, Yiannopoulou et al. suggested a potential relationship between *H. pylori* infection as an independent environmental risk factor for migraine without aura. In their case–control study, 49 patients with migraine without aura were compared with 51 control subjects without a history of primary headache. They showed that the prevalence of *H. pylori* infection was significant higher in patients with migraine headache than in controls (p=0.016).

**Functional gastrointestinal disorders**

Boccia et al. conducted a case–control study involving 50 migraineous children with functional GID and 19 control subjects, as well as 10 migraineous children without such disorders and nine healthy children in order to evaluate the effects of gastric stasis on migraine attacks. The gastric emptying time was shortened by using a calcium-channel blocker (flunarizine), which has demonstrated efficacy in the treatment of migraine attacks. Flunarizine treatment resulted in a remarkable improvement of both the GI and headache symptoms; although the clinical findings could not be definitively explained, the authors postulated that ion-channel mutations play a role in the pathogenesis of migraine.

The relationship between gastric stasis and migraine was also evaluated by Aurora et al. in a case–control study involving 10 migraine patients along with 10 age- and sex-matched controls. The authors showed that gastric stasis is not only present ictally but also interictally (as measured by gastric scintigraphy). The finding of interictal gastric stasis suggests that nausea in migraine could be related to a central cause rather than to the gastric stasis—migraine may consequently not be an episodic manifestation in an otherwise healthy person, but rather represent the expression of a dysregulated autonomic system. This hypothesis was supported by the findings of Maniyar et al., who performed a positron-emission tomography study in the premonitory phase of nitroglycerin-induced migraine. Their subjects with nausea showed activation in the rostral dorsal medulla and periaqueductal gray, while no activation of these central structures related to nausea were seen in the nonnausea group.

**Infantile colic**

In a case–control study, Romanello et al. investigated the association between migraine and infantile colic in 208 consecutive children aged between 6 to 18 years. Most (72.6%, n=151) of the children with migraine also suffered from infantile colic. The authors postulated a molecular link between these two conditions in the form of CGRP, which is released during migraine attacks and is potentially also involved in the pathogenesis of abdominal pain by causing inflammation of sensory GI neurons. In a multivariable analysis of a population-based, prospective 18-year follow-up cohort, Sillanpää and Saarinen showed that infantile colic was significantly associated with a nearly threefold increase in the risk of future migraine without aura.

**Endocrine mechanisms**

The involvement of CGRP was postulated by Kurth et al. in their study of 99 patients with upper GI symptoms and migraine. They found that the prevalence of idiopathic dyspepsia was higher in patients with migraine than in healthy controls (n=488). A nine-year prospective study of 81 obese patients with migraine headache by Gunay et al. showed improvement of migraine after bariatric surgery for weight loss. The resolution of migraine symptoms was independent of the improvement of migraine-associated comorbidities. Postoperative endocrine changes or reduction in the adipokine burden were discussed by those authors as potential contributing causes. Amery and Forget conducted a 51-Cr EDTA gut-permeability
test, and found that gut permeability was significantly higher in 16 patients with recurrent abdominal pain than in 11 control children and 10 healthy young adults (p<0.0006). Recurrent abdominal pain in migrainous children may be due to increased gut permeability allowing compounds to pass the gut-blood barrier that induce cerebral vasoconstriction or exert damaging neuronal effects.

CONCLUSIONS

The clinical and pathophysiological relationships between migraine and GID are intriguing. However, the reported data suffer from great heterogeneity in their gathering and analysis techniques, making a meaningful comparison between studies impossible. Definitive conclusions can therefore not be drawn yet. Furthermore, since migraine is associated with multiple GI conditions rather than one particular GI disease, there is no single pathophysiology interpretation of the association. The pathophysiological mechanisms remain elusive regardless of the GI diseases associated with migraine. Since GI bacteria have repeatedly been implicated in shaping the character of the immune system, including at remote locations, it would be interesting to investigate whether modifying the gut microbiota or even adding probiotics could affect migraines. For the time being, from a strict clinical point of view, an awareness of the potential relationship between these two disorders can lead to prompt diagnosis and appropriate therapy for a highly disabling condition.

Conflicts of Interest

The authors have no financial conflicts of interest.

REFERENCES

1. Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia 2010;30:1065-1072.
2. Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009;27:321-334.
3. Wöber-Bingöl C. Epidemiology of migraine and headache in children and adolescents. Curr Pain Headache Rep 2013;17:341.
4. Bradbeer L, Thakkar S, Liu A, Nanan R. Childhood headache and H. pylori—a possible association. Aust Fam Physician 2013;42:134-136.
5. Aamodt AH, Stonner LJ, Hagen K, Zwart JA. Comorbidity of headache and gastrointestinal complaints. The Head-HUNT Study. Cephalalgia 2008;28:144-151.
6. Tellez-Zenteno JF, Garcia-Ramos G, Zermelho-Pohls F, Velazquez A, GGSM. Demographic, clinical and comorbidity data in a large sample of 1,147 patients with migraine in Mexico City. J Headache Pain 2005;6:128-134.
7. Waerbe C, Moskowitz MA. Migraine as an inflammatory disorder. Neurology 2005;64(10 Suppl 2):S59-S15.
8. van Hemert S, Breedveld AC, Rovers JM, Vermeiden JP, Witteman BJ, Smits MG, et al. Migraine associated with gastrointestinal disorders: review of the literature and clinical implications. Front Neurol 2014;5:241.
9. Gunay Y, Jamal M, Capper A, Eid A, Heitshusen D, Samuel I. Rux-en-Y gastric bypass achieves substantial resolution of migraine headache in the severely obese: 9-year experience in 81 patients. Surg Obes Relat Dis 2013;9:55-62.
10. Carabotti M, Scirocchi A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015;28:203-209.
11. Parkman HP. Migraine and gastroparesis from a gastroenterologist’s perspective. Headache 2013;53 Suppl 1:1-10.
12. Newman LC. Why triptan treatment can fail: focus on gastrointestinal manifestations of migraine. Headache 2013;53 Suppl 1:11-16.
13. Kurth T, Holtmann G, Neufang-Hüber J, Gerken G, Diener HC. Prevalence of unexplained upper abdominal symptoms in patients with migraine. Cephalalgia 2006;26:506-510.
14. Carson L, Lewis D, Tsou M, McGuire E, Surran B, Miller C, et al. Abdominal migraine: an under-diagnosed cause of recurrent abdominal pain in children. Headache 2011;51:707-712.
15. Roberts JE, deShazo RD. Abdominal migraine, another cause of abdominal pain in adults. Am J Med 2012;125:1135-1139.
16. Cole JA, Rothman KJ, Cabral HJ, Zhang Y, Farraye EA. Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. BMC Gastroenterol 2006;6:26.
17. Ford S, Finkel AG, Isacks KL. Migraine in patients with inflammatory bowel disorders. J Clin Gastroenterol 2009;43:499.
18. Mormile R. Celiac disease and migraine: is there a common back-stage? Int J Colorectal Dis 2014;29:1571.
19. Yiannopoulou KG, Efthymiou A, Karydakis K, Arhimandritis A, Bovareto N, Tzivras M. Helicobacter pylori infection as an environmental risk factor for migraine without aura. J Headache Pain 2007;8:329-333.
20. Konturek PC, Brozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011;62:591-599.
21. Roberts MS. Cluster belly: a variant of irritable bowel syndrome. Headache 2014;54:1644-1646.
22. Aydinlar EI, Dikmen PY, Tiftikci A, Saruc M, Aksu M, Gunsoy HG, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache 2013;53:514-525.
23. Watson WC, Sullivan SN, Corke M, Rush D. Globus and headache: common symptoms of the irritable bowel syndrome. Can Med Assoc J 1978;118:387-388.
24. Soares RL, Moreira-Filho PF, Maneschy CP, Breijão JF, Schmidtme NM. The prevalence and clinical characteristics of primary headache in irritable bowel syndrome: a subgroup of the functional somatic syndromes. Arq Gastroenterol 2013;50:281-284.
25. Dimitrova AK, Ungaro RC, Lebwohl B, Lewis SK, Tennyson CA, Green MW, et al. Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache 2013;53:344-355.
26. Gabrielli M, Cremonini F, Fiore G, Addolorato G, Padalino C, Candelli M, et al. Association between migraine and celiac disease: results from a preliminary case-control and therapeutic study. Ann Gastroenterol 2003;16:98-103.
27. Ford S, Finkel AG, Isacks KL. Migraine in patients with inflammatory bowel disorders. Can Med Assoc J 1978;118:387-388.
28. Soares RL, Moreira-Filho PF, Maneschy CP, Breijão JF, Schmidtme NM. The prevalence and clinical characteristics of primary headache in irritable bowel syndrome: a subgroup of the functional somatic syndromes. Arq Gastroenterol 2013;50:281-284.
29. Konturek PC, Brozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011;62:591-599.
30. Robbins MS. Cluster belly: a variant of irritable bowel syndrome. Headache 2014;54:1644-1646.
31. Aydinlar EI, Dikmen PY, Tiftikci A, Saruc M, Aksu M, Gunsoy HG, et al. IgG-based elimination diet in migraine plus irritable bowel syndrome. Headache 2013;53:514-525.
32. Watson WC, Sullivan SN, Corke M, Rush D. Globus and headache: common symptoms of the irritable bowel syndrome. Can Med Assoc J 1978;118:387-388.
33. Soares RL, Moreira-Filho PF, Maneschy CP, Breijão JF, Schmidtme NM. The prevalence and clinical characteristics of primary headache in irritable bowel syndrome: a subgroup of the functional somatic syndromes. Arq Gastroenterol 2013;50:281-284.
34. Dimitrova AK, Ungaro RC, Lebwohl B, Lewis SK, Tennyson CA, Green MW, et al. Prevalence of migraine in patients with celiac disease and inflammatory bowel disease. Headache 2013;53:344-355.
35. Gabrielli M, Cremonini F, Fiore G, Addolorato G, Padalino C, Candelli M, et al. Association between migraine and celiac disease: results from a preliminary case-control and therapeutic study. Ann Gastroenterol 2003;16:98-103.
vomiting syndrome, migraine, and epilepsy: a common underlying disorder? *Headache* 2003;43:407-409.

32. Zaki EA, Freilinger T, Klopfstock T, Baldwin EE, Heisner KR, Adams K, et al. Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. *Cephalalgia* 2009;29:719-728.

33. Christensen CJ, Johnson WD, Abell TL. Patients with cyclic vomiting pattern and diabetic gastropathy have more migraines, abnormal electrogastrograms, and gastric emptying. *Scand J Gastroenterol* 2008;43:1076-1081.

34. Monro J, Carini C, Brostoff J. Migraine is a food-allergic disease. *Lancet* 1984;2:719-721.

35. Alpay K, Ertas M, Orhan EK, Ustay DK, Lieners C, Baykan B. Diet restriction in migraine, based on IgG against foods: a clinical double-blind, randomised, cross-over trial. *Cephalalgia* 2010;30:829-837.

36. Mitchell N, Hewitt CE, Jayakody S, Islam M, Adamson J, Watt I, et al. Randomised controlled trial of food elimination diet based on IgG antibodies for the prevention of migraine like headaches. *Nutr J* 2011;10:85.

37. Bektas H, Karabulut H, Doganay B, Acar B. Allergens might trigger migraine attacks. *Acta Neurol Belg* 2017;117:91-95.

38. Egger J, Carter CM, Wilson J, Turner MW, Soothill JF. Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. *Lancet* 1983;2:865-869.

39. Hosseinzadeh M, Khorarvi A, Saki K, Ranjar B. Evaluation of Helicobacter pylori infection in patients with common migraine headache. *Arch Med Sci* 2011;7:844-849.

40. Boccia G, Del Giudice E, Crisanti AF, Strisciuglio C, Romano A, Staiano A. Functional gastrointestinal disorders in migrainous children: efficacy of flunarizine. *Cephalalgia* 2006;26:1214-1219.

41. Aurora SK, Kori SH, Barrodale P, McDonald SA, Haseley D. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. *Headache* 2006;46:57-63.

42. Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. The origin of nausea in migraine—a PET study. *J Headache Pain* 2014;15:84.

43. Romanello S, Spiri D, Marcuzzi E, Zanin A, Boizeau P, Riviere S, et al. Association between childhood migraine and history of infantile colic. *JAMA* 2013;309:1607-1612.

44. Sillanpää M, Saarinen M. Infantile colic associated with childhood migraine: a prospective cohort study. *Cephalalgia* 2015;35:1246-1251.

45. Amery WK, Forget PP. The role of the gut in migraine: the oral 51-Cr EDTA test in recurrent abdominal pain. *Cephalalgia* 1989;9:227-229.

46. Rao VP, Poutahidis T, Fox JG, Erdman SE. Breast cancer: should gastrointestinal bacteria be on our radar screen? *Cancer Res* 2007;67:847-850.

47. Poutahidis T, Cappelle K, Levkovitch T, Lee CW, Doulberis M, Ge Z, et al. Pathogenic intestinal bacteria enhance prostate cancer development via systemic activation of immune cells in mice. *PLoS One* 2013;8:e73933.

48. Ruggieri M, Incorpora G, Polizzi A, Parano E, Spina M, Pavone P. Low prevalence of neurologic and psychiatric manifestations in children with gluten sensitivity. *J Pediatr* 2008;152:244-249.

49. Park JW, Cho YS, Lee SY, Kim ES, Cho H, Shin HE, et al. Concomitant functional gastrointestinal symptoms influence psychological status in Korean migraine patients. *Gut Liver* 2013;7:668-674.

50. Hirst B, Noble B. Migraine as a cause of persistent nausea or vomiting in palliative care: a case series. *J Pain Symptom Manage* 2009;37:918-922.